Methods of Treating Giardiasis Using FDA-Approved Compounds


This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of Giardia in humans
  • Treatment of Giardia in animals - dogs and cats
 These compounds have currently been approved for human and veterinary uses of other indications which provides an opportunity to greatly reduce risk and pre-market investments both in terms of time and costs associated with development and regulatory approval for new Giardia applications including the drug resistant Giardiasis.


Development Stage:
  • Early-stage
  • Pre-clinical
  • In vitro data available


Inventors:

Wei Zheng (NCATS)  ➽ more inventions...

Catherine Chen (NCATS)  ➽ more inventions...

Juan Marugan (NCATS)  ➽ more inventions...

Noel Southall (NCATS)  ➽ more inventions...

Christopher Austin (NCATS)  ➽ more inventions...

Osnat Herzberg

Andrey Galkin


Intellectual Property:
U.S. Pat: 9,173,898 issued 2015-11-03
PCT Application No. PCT/US2011/055902
US Application No. 61/411,509

Publications:
Chen CZ, et al. PMID 21078930

Collaboration Opportunity:

The NHGRI is seeking stateents of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Novel Compounds for Treatment of Giardiasis. For collaboration opportunities, please contact Claire Driscoll, NHGRI, at cdriscol@mail.nih.gov.


Licensing Contact:
Suryanarayana Vepa, Ph.D.
Email: sury.vepa@nih.gov
Phone: 301-217-9197

OTT Reference No: E-211-2010/1
Updated: Aug 17, 2012